Long COVID is a condition where debilitating symptoms can persist for months after aCOVID-19 infection. This study aims to evaluate the effects of NE3107 on severalneurological symptoms reported in people with Long COVID including difficultyconcentrating or remembering things ("brain fog") and fatigue.Researchers will compare NE3107 to a placebo (a look-alike substance that contains nodrug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID.Participants will: - Take NE3107 or a placebo twice daily for 84 days - Visit the clinic 5 times for checkups and tests and have a follow up phone call
Not Provided
Drug: NE3107
20 mg Capsule
Other Name: bezisterim
Drug: Placebo
placebo capsule
Inclusion Criteria:
- 18 years to 64 years of age
- diagnosed with Long COVID with symptoms of fatigue and brain fog for at least 3
months
- agree to use birth control measures
- provide voluntary consent
- willing to allow blood collection
- pass all screening tests and procedures
Exclusion Criteria:
- has received a COVID-19 vaccination within 30 days
- previous admission to the intensive care unit for COVID-19
- medical history of major mental or physical illness prior to COVID-19 infection
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Jacksonville, Florida, United States
Clinical Trial Site
Silver Spring, Maryland, United States
Clinical Trial Site
Farmington Hills, Michigan, United States
Penelope Markham, PhD
pmarkham@bioviepharma.com
Not Provided